Literature DB >> 6883352

The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.

J M Venditti.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6883352

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  14 in total

1.  Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.

Authors:  G Bernhardt; H Reile; H Birnböck; T Spruss; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.

Authors:  L R Kelland; M Jones; G Abel; M Valenti; J Gwynne; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Is the P388 murine tumor no longer adequate as a drug discovery model?

Authors:  T H Corbett; F A Valeriote; L H Baker
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

4.  Rapid chemosensitivity testing of human lung tumor cells using the MTT assay.

Authors:  S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.

Authors:  J E Talmadge; M A Chirigos
Journal:  Springer Semin Immunopathol       Date:  1985

Review 6.  Predictive testing in cancer chemotherapy. I. In vivo.

Authors:  P H Slee; A T Van Oosterom; E A De Bruijn
Journal:  Pharm Weekbl Sci       Date:  1985-06-21

7.  Cytotoxicity Evaluation of Mycotoxins by an MTT-Bioassay.

Authors:  G H Reubel; M Gareis; W M Amselgruber
Journal:  Mycotoxin Res       Date:  1987-09       Impact factor: 3.833

8.  In vitro and in vivo chemotherapy screening of the divalent cation chelator 1,10-orthophenanthroline.

Authors:  P S Cohen; S D Smith
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines.

Authors:  C J Brindley; R B Pedley; P Antoniw; E S Newlands
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Effect of cisplatin on primary tumour growth and liver metastases in the M 5076 reticulum sarcoma: implication for new screening modalities.

Authors:  M Schirner; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.